Context Capital Management
DMIIR icon

Context Capital Management’s Drugs Made In America Acquisition II Corp Right DMIIR Stock Holding History

Context Capital Management’s Portfolio DMIIR Stock Details DMIIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$48.2K Hold
750,000
– – ﹤0.01% 319
2026
Q2 		$60K Hold
750,000
– – ﹤0.01% 305
2026
Q1 		$60K Hold
750,000
– – ﹤0.01% 267
2025
Q4 		$105K Buy
+750,000
New +$107K ﹤0.01% 209

Other funds holding DMIIR

Picton Mahoney Asset Management
Picton Mahoney Asset Management Toronto, Ontario, Canada $14.8B AUM 38.11% 1-Year Est. Return
Wolverine Asset Management
Wolverine Asset Management Chicago, Illinois $14.9B AUM 3.61% 1-Year Est. Return
Wealthspring Capital
Wealthspring Capital West Harrison, New York $447M AUM 5.09% 1-Year Est. Return
Commonwealth of Pennsylvania Public School Employees Retirement System
Commonwealth of Pennsylvania Public School Employees Retirement System Harrisburg, Pennsylvania $21.9B AUM 28.42% 1-Year Est. Return
Periscope Capital
Periscope Capital Toronto, Ontario, Canada $990M AUM 4.73% 1-Year Est. Return
Mint Tower Capital Management
Mint Tower Capital Management Amsterdam, Netherlands $589M AUM 6.02% 1-Year Est. Return
StoneX Group
StoneX Group New York $2.75B AUM 24.13% 1-Year Est. Return
ABC Arbitrage
ABC Arbitrage Paris, France $1.02B AUM 30.46% 1-Year Est. Return

Context Capital Management's DMIIR Position: Q3 2026 in Review

Context Capital Management held its Drugs Made In America Acquisition II Corp Right (DMIIR) position steady in Q3 2026 at 750,000 shares worth $48.2K. The position accounts for ﹤0.01% of the portfolio, ranked #319.

Context Capital Management first reported a position in DMIIR in Q4 2025 and has held it in 4 quarters since. The position peaked at $105K in Q4 2025. 9 funds tracked by Wall St. Rank hold DMIIR as of Q3 2026.

  • Context Capital Management held 750,000 shares of Drugs Made In America Acquisition II Corp Right worth $48.2K as of Q3 2026.
  • Context Capital Management left its Drugs Made In America Acquisition II Corp Right share count unchanged in Q3 2026.
  • Drugs Made In America Acquisition II Corp Right made up ﹤0.01% of Context Capital Management's portfolio in Q3 2026, its #319 holding.
  • Context Capital Management first reported a position in Drugs Made In America Acquisition II Corp Right in Q4 2025 and has held it in 4 quarters since.
  • Context Capital Management's Drugs Made In America Acquisition II Corp Right position peaked at $105K in Q4 2025.
  • 9 funds tracked by Wall St. Rank held Drugs Made In America Acquisition II Corp Right as of Q3 2026.

Based on Context Capital Management's 13F filing for Q3 2026, filed 4 Nov 2026.